NASHVILLE, TENNESSEE — A second-generation anti-CD40L monoclonal antibody suppresses multiple sclerosis (MS) disease activity on MRI to an uncommonly high degree, new trial data suggested.
Investigational MS Med Nearly Eliminates... - My MSAA Community
Investigational MS Med Nearly Eliminates Disease Activity on MRI
Written by
BettysMom
To view profiles and participate in discussions please or .
Read more about...
6 Replies
•
that is totally a dream come true!
Hope the Phase 3 trials are positive as well.
No evidence of increased infection risk! That could be a game changer.
This could be a game changer! Hope the next phase has great results as well!
Thank you
Thank you for posting this.
Not what you're looking for?
You may also like...
Blood Test for MS Activity Gets FDA Breakthrough Designation
The US Food and Drug Administration (FDA) has granted breakthrough device designation to the...
Intermittent Fasting Shows Promise in Multiple Sclerosis
Intermittent fasting -- defined as restricting food and drink to 500 calories a day, twice a...
More Research on the Gut Microbiome & MS
More research on the gut microbiome and MS, which relates directly to diet, a favorite topic of...
Two MS Medications Appear on FDA’s Shame List
Apparently, Ampyra and Tecfidera don't want to play nice with generic making companies:...
We are celebrating MSAA's 53rd Anniversary!
Lemtrada
DO MRI STUDIES ACCURATELY REFLECT YOUR DISEASE STATUS?
types of MS (FYI)
PPMS... 
